Fairview Specialty Pharmacy’s Compounding Split: The 2026 Gap Guide

Introduction: Why “Fairview Specialty Pharmacy” Searches Are Missing Half the Story

Most people who search for “Fairview specialty pharmacy” have a practical goal. They want to reach the pharmacy, transfer a prescription, check refill status, confirm insurance participation, or understand what the upcoming 2027 UnitedHealthcare Medicare Advantage exit means for them.

Few searchers realize that Fairview operates two distinct pharmacy divisions: Fairview Specialty Pharmacy and Fairview Compounding Pharmacy. The two share a brand and even overlapping addresses. However, they hold different accreditations, have different histories, and have faced different levels of regulatory scrutiny.

This guide explains the split, why it exists, and what FDA Form 483 inspection findings revealed about the compounding side. It also explains what patients who need custom formulations, such as bioidentical hormones, pediatric doses, or allergen-free versions, can do when Fairview’s specialty arm cannot fill their prescription.

The timing matters. Fairview is consolidating its pharmacy operations into a new Seven Lakes facility and will lose UnitedHealthcare Medicare Advantage network status on January 1, 2027. For many patients, understanding this internal split has become urgent.

What Is Fairview Specialty Pharmacy?

A specialty pharmacy dispenses FDA-approved, commercially manufactured drugs exactly as the manufacturer made them. It does not alter the dose, the dosage form, or the ingredients.

Fairview Specialty Pharmacy serves patients with complex and chronic conditions, including rheumatoid arthritis, Crohn’s disease, multiple sclerosis, cystic fibrosis, hepatitis C, psoriasis, cancer, solid organ transplant, and hemophilia. Its medications are administered by injection, infusion, or orally.

History, Locations, and Accreditation

Fairview Specialty Pharmacy was founded in 1997 to help University of Minnesota transplant patients manage the complex medication regimens required after organ transplantation. It has since grown into one of the most advanced transplant specialty pharmacies in the industry.

The pharmacy operates primarily from two locations:

• 711 Kasota Ave SE, Minneapolis, MN
• 3650 Victoria St N, Shoreview, MN

It maintains separate phone lines for “Specialty and Rare Disease Patients” and “Transplant Patients.”

Its credentials are strong. Fairview Specialty Pharmacy holds URAC Specialty Pharmacy Accreditation plus a Rare Disease Pharmacy Center of Excellence Designation, a distinction held by only a few pharmacies nationally. The National Association of Specialty Pharmacy (NASP) named it Specialty Pharmacy of the Year in 2019. It is also a founding member of the Health System Owned Specialty Pharmacy (HOSP) Alliance. Fairview promotes a 91 “loyalty rating” and an average call answer time of under 20 seconds.

What Fairview Specialty Pharmacy Cannot Do

By structural and regulatory definition, a specialty pharmacy cannot customize a dose, change a dosage form, add flavoring, or remove allergens. It dispenses manufacturer products as they are.

Many specialty medications are also Limited Distribution Drugs (LDDs). According to a 2025 Drug Channels Institute analysis, 34% of specialty products are handled by a single pharmacy. IPD Analytics defines an LDD as a drug that the manufacturer limits to 24 or fewer specialty pharmacies, and notes that roughly 80% of LDDs move through fewer than 10 pharmacies. These tightly controlled distribution channels leave specialty pharmacies no flexibility to modify the products they handle.

The specialty pharmacy trade group SPAARx has stated plainly that specialty pharmacy and compounding are “dissimilar” practices. Specialty pharmacies dispense FDA-approved, commercially available drugs. Compounding is an extemporaneous preparation practice. Patients often do not learn this distinction until they need a formulation that Fairview Specialty cannot provide.

The Hidden Split: Fairview Compounding Pharmacy Is a Separate Division

Fairview Compounding Pharmacy is a legally and operationally distinct entity from Fairview Specialty Pharmacy, despite shared branding and overlapping addresses.

Its locations are listed as 711C Kasota Ave SE, Minneapolis and 3650 Victoria St N, Shoreview. The subtle “711C” in the Minneapolis address signals a separate operation within the same campus.

What the Compounding Division Offers

Fairview Compounding Pharmacy provides both 503A and 503B sterile and non-sterile compounding services. Examples include:

• Low-dose naltrexone
• Bioidentical hormone therapy
• Topical pain creams
• Allergy immunotherapy serums
• Orthopedic injections
• Surgical pain pumps

The division states that it complies with USP Chapter <795> (non-sterile compounding) and USP Chapter <797> (sterile compounding).

The 2018 FDA Form 483 Sterile-Practice Citations

According to the FDA’s published inspection documents, a 2018 inspection of Fairview Compounding Pharmacy identified several deviations from sterile practice standards:

• Non-sterilized and non-depyrogenated equipment used in sterile drug preparation
• Inadequate frequency of sporicidal disinfection
• Insufficient glove changes in ISO 5 (cleanroom) areas

Following the inspection, the FDA referred the case to the Minnesota Board of Pharmacy in 2019. In its published response to the FDA, Fairview Pharmacy Services stated that the issues had been corrected.

These findings matter because sterile compounding carries real contamination risk. Products prepared in cleanroom environments are often injected or infused, so lapses in sterility controls can directly affect patient safety. The record shows that even the internal compounding arm of a well-accredited health system has a documented history of regulatory citations. Patients and prescribers benefit from asking about current compliance status rather than assuming it.

Why Fairview Keeps These Two Pharmacies Separate

The separation follows regulatory logic. Specialty pharmacy accreditation (such as URAC) and compounding oversight (state board of pharmacy licensing and USP chapter compliance) are fundamentally different frameworks.

In Minnesota, Minn. R. 6800.3300 requires all licensed pharmacies that compound nonsterile drugs to follow USP Chapter 795, and sterile compounders to follow USP Chapter 797. Minnesota Statute 151.15 makes unauthorized or unlicensed compounding or dispensing of legend drugs unlawful. Compounding therefore carries its own compliance burden, separate from specialty dispensing.

Keeping the divisions apart also limits liability exposure. It insulates the specialty pharmacy’s URAC accreditation and Rare Disease Center of Excellence designation from compliance risks specific to sterile compounding.

The operational picture adds a layer of nuance. In fall 2025, Fairview Pharmacy Services began consolidating its Specialty, Mail Services, Home Infusion, Compounding, Wholesale, ClearScript, and IntegraDose teams into a new Seven Lakes facility. The site added automation such as Parata MAX 2 vial-filling machines and the first U.S. installation of BD Rowa Vmax in a central-fill pharmacy. Physical proximity, however, does not equal structural integration. The divisions remain separate even under one roof.

The Patient-Facing Gap This Split Creates

The core problem is simple. Patients assume “Fairview Specialty Pharmacy” can fill any prescription their Fairview provider writes. Custom formulations fall outside its scope by design.

Who Falls Into the Gap

Several groups of patients are most likely to encounter this gap:

• Patients needing custom-dose medications that are not available in commercial strengths
• Patients requiring allergen-free formulations free of dyes, fillers, or preservatives
• Patients seeking BHRT (bioidentical hormone replacement therapy) with doses adjusted based on lab results
• Pediatric patients who need age- or weight-specific dosing in flavored, easy-to-administer forms
• Patients needing a discontinued or shortage medication recreated in an alternative strength or form

Compounding Existing Friction in the Specialty Pharmacy Process

The gap sits on top of friction that already exists in specialty pharmacy nationally. First-pass prior authorization denial rates for specialty medications run between 25% and 40%. According to Surescripts, half of specialty pharmacists report that the average specialty prescription takes at least four days to fill, and waits of 7 to 10 days are not uncommon.

Reputation signals point to similar strain at Fairview. Fairview Specialty Pharmacy’s Indeed employee reviews average 2.8 out of 5, with reviewers describing a “high-stress” call-center environment. Third-party aggregator data shows 3.6 stars across 89 reviews, including at least one patient account describing the pharmacy as feeling aligned with the payer rather than the patient during approval of a costly medication.

When a prescription already faces denial risk and multi-day delays, many patients search for alternatives rather than wait on an internal referral path between Fairview’s two pharmacy divisions.

The 2027 UnitedHealthcare Exit Adds Urgency

Starting January 1, 2027, Fairview Health Services, including its pharmacies, will be out-of-network for UnitedHealthcare Medicare Advantage plans. An estimated 33,000 to 35,000 UHC Medicare Advantage patients are affected.

Fairview has said that frequent coverage changes, denials, and payment issues made it difficult for patients to access timely care. In October 2026, Fairview filed a lawsuit against UnitedHealthcare, alleging that the insurer’s 2027 network directory listings inaccurately told seniors that Fairview’s hospitals and clinics would remain in network.

For Medicare Advantage members who want to stay in network with Fairview, in-network options going forward include:

• BCBS Minnesota
• HealthPartners
• Medica

The exit also creates a compounding ripple effect. Patients who lose in-network access to Fairview Specialty Pharmacy may also lose convenient access to Fairview Compounding Pharmacy for custom prescriptions tied to the same health system. That makes the current period an ideal time to identify a nationwide compounding alternative that does not depend on a single health system’s network status.

How to Determine Which Fairview Pharmacy (or Alternative) Is Needed

A simple decision framework can help patients and caregivers route prescriptions correctly.

Use Fairview Specialty Pharmacy if the prescription is for an FDA-approved, commercially manufactured specialty drug at a standard dose and form.

Use a compounding pharmacy if the prescription requires any of the following:

• A nonstandard dose or strength
• Flavoring or an alternative dosage form
• Removal of allergens, dyes, fillers, or preservatives
• Pediatric adaptation
• BHRT titration based on lab results

In those cases, the patient needs either Fairview’s internal compounding division or an outside PCAB-accredited alternative.

Patients should ask their prescriber or pharmacy a few direct questions:

1. Is this a commercial product or a compounded formulation?
2. Is the pharmacy a 503A or 503B facility?
3. What accreditations and compliance certifications does it currently hold?

Patients are not required to use a health system’s in-house compounding division, even if their provider is Fairview-affiliated. Prescriptions can be routed to any licensed, accredited compounding pharmacy that is authorized to serve the patient’s state.

A Nationwide, Verified-Compliance Alternative: Nationwide Compounding Rx®

Nationwide Compounding Rx® is a Scottsdale, Arizona-based compounding pharmacy positioned to fill the exact gap created by Fairview’s specialty and compounding split. It partners directly with prescribing practices and also supports patients through dedicated service channels.

The pharmacy is PCAB accredited (Pharmacy Compounding Accreditation Board) and USP 800 compliant. These verified, current compliance standards give prescribers and patients a clear answer to the question of quality, which is especially relevant given the documented 2018 citations at Fairview Compounding Pharmacy.

Services That Match the Gap

Nationwide Compounding Rx® offers formulations that align closely with the patient groups most affected by the split:

• BHRT: Customized hormone formulations for menopause, andropause, and hormonal imbalance, adjustable at each refill based on lab results.
• Pediatrics: Age- and weight-specific medications for newborns through teens, available as capsules, liquids, troches, suppositories, and kid-friendly forms such as flavored liquids, popsicles, and suckers. Flavor options include cherry, bubblegum, strawberry, marshmallow, and more.
• Allergen-free formulations: Preparations free of dyes, fillers, preservatives, and allergens.
• Pain management and dermatology: Topical creams, gels, and ointments that localize treatment and reduce systemic side effects, plus custom topicals for acne, rosacea, eczema, psoriasis, and scarring.

The pharmacy can also recreate discontinued or unavailable medication strengths, and it produces both sterile and non-sterile formulations.

Speed, Access, and Compliance Advantages

• Turnaround: A 1 to 2 business day turnaround, with same-day pickup available for some medications at the Scottsdale location. This compares favorably with the 4 to 10 day waits common in specialty pharmacy nationally.
• Shipping reach: Nationwide shipping across licensed states, using a tiered system: fully licensed states, states where only non-sterile compounding is currently available (with sterile licensing pending), and states where licensing is still pending. Availability depends on medication type, state regulations, and prescription requirements. This offers continuity regardless of insurance network changes like the 2027 UHC and Fairview exit.
• Quality controls: High-grade chemicals sourced exclusively from FDA-inspected and cleared vendors, backed by independent third-party testing.
• Provider partnership: A structured model of Connect, Collaborate, Create, Care, supported by secure provider and patient portals for prescription submission, order tracking, and refill management.

Conclusion: Knowing the Difference Protects Access to Care

Fairview Specialty Pharmacy and Fairview Compounding Pharmacy are separate entities with different accreditations, services, and regulatory histories. Most patients never learn this until a prescription is denied or delayed.

Several developments make the split more important now. The 2027 UnitedHealthcare Medicare Advantage exit, the Seven Lakes consolidation, and Fairview Compounding’s documented 2018 FDA citations all add uncertainty for patients who need custom formulations.

Verified, nationwide compounding alternatives offer a practical way to remove that uncertainty. Rather than navigating internal health-system silos, patients and prescribers can choose a pharmacy based on current accreditation, transparent compliance, and reliable turnaround.

Next Steps: Talk to a Compounding Pharmacy That Shows Its Work

Patients and providers facing a custom-dose, allergen-free, BHRT, or pediatric formulation need can contact Nationwide Compounding Rx® directly to confirm compliance credentials, state availability, and turnaround timelines before a prescription is delayed.

Healthcare providers can also explore the Connect, Collaborate, Create, Care partnership process to establish an ongoing compounding relationship that is independent of any single health system’s internal pharmacy structure.

Contact Nationwide Compounding Rx®:

• Phone: (480) 499-8379
• Fax: 480-699-5341
• Website: nationwidecompounding.com
• Portals: Secure Provider Portal and Patient Portal available through the website
• Address: 14000 N. Hayden Rd., Suite 104, Scottsdale, AZ 85260
• Hours: Monday–Friday, 7:00 AM–3:30 PM